US 12,186,315 B2
Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
John Ford, Cambridgeshire (GB); Patrick Round, Suffolk (GB); John Kastelein, Amsterdam (NL); Atsuhiro Kawaguchi, Osaka (JP); Koichi Tomiyasu, Osaka (JP); and Kozo Oka, Osaka (JP)
Assigned to NewAmsterdam Pharma B.V., Naarden (NL)
Filed by NewAmsterdam Pharma B.V., Naarden (NL)
Filed on Apr. 3, 2023, as Appl. No. 18/130,178.
Application 16/844,996 is a division of application No. 15/117,154, granted, now 10,653,692, issued on May 19, 2020, previously published as PCT/NL2014/050068, filed on Feb. 5, 2014.
Application 18/130,178 is a continuation of application No. 17/226,655, filed on Apr. 9, 2021, granted, now 11,642,344.
Application 17/226,655 is a continuation of application No. 16/844,996, filed on Apr. 9, 2020, granted, now 11,013,742, issued on May 25, 2021.
Prior Publication US 2024/0024315 A1, Jan. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01)] 4 Claims
 
1. An oral daily dosage form comprising 1 to 25 mg of the compound:

OG Complex Work Unit Chemistry
(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof.